A first-in-class dual GIP and GLP-1 receptor agonist showing superior weight loss and glycemic outcomes compared to single-receptor GLP-1 agents.
Sourced from Ascension Peptides. Verified purity, third-party tested. COA included.
Buy Now →Tirzepatide is a synthetic 39-amino acid peptide developed by Eli Lilly and Company that functions as a dual agonist at two incretin hormone receptors: the glucose-dependent insulinotropic polypeptide receptor (GIPR) and the glucagon-like peptide-1 receptor (GLP-1R). It represents a significant departure from earlier single-target incretin therapies and is among the most closely studied metabolic peptides of the past decade.
The compound traces its origins to Eli Lilly’s broader research program in dual incretin pharmacology, with early preclinical work published in the mid-2010s. The core scientific premise rested on a well-established observation: GIP and GLP-1 together account for most of the postprandial insulin secretion in healthy individuals, but GIP’s contribution is severely blunted in people with type 2 diabetes. Researchers reasoned that a molecule capable of simultaneously engaging both receptors might restore that synergy and produce metabolic benefits exceeding what either pathway could achieve alone.
Structurally, tirzepatide was engineered from a GIP analog backbone. Its 39-residue sequence incorporates a C20 fatty diacid moiety attached via a linker at lysine-26, a modification borrowed from the long-acting insulin and GLP-1 analog engineering playbook. This lipid tail enables reversible albumin binding, extending the compound’s half-life to approximately five days and making once-weekly subcutaneous injection practical.
Tirzepatide received U.S. Food and Drug Administration approval in May 2022 under the brand name Mounjaro for type 2 diabetes management, followed by a second approval in November 2023 under the brand name Zepbound specifically for chronic weight management in adults with obesity or overweight with at least one weight-related comorbidity. Regulatory agencies in the European Union, the United Kingdom, Japan, and several other jurisdictions have granted analogous approvals.
The clinical development program spans two major trial families: SURPASS (diabetes) and SURMOUNT (obesity), together enrolling tens of thousands of participants across more than 30 countries. These trials established tirzepatide’s clinical profile with an unusual degree of statistical rigor and generated data sets that researchers continue to mine for secondary endpoints ranging from cardiovascular events to kidney function and liver fat.
For researchers, tirzepatide offers a chemically stable, well-characterized tool compound for investigating the intersection of incretin biology, adipose metabolism, and cardiometabolic disease.
Tirzepatide’s defining pharmacological feature is simultaneous, balanced agonism at both the GIP receptor and the GLP-1 receptor. In healthy physiology, GIP and GLP-1 are released from enteroendocrine K and L cells, respectively, following nutrient ingestion. Both peptides amplify glucose-stimulated insulin secretion from pancreatic beta cells in a glucose-dependent fashion — meaning they potentiate insulin release only when blood glucose is elevated, providing an intrinsic safeguard against hypoglycemia. Tirzepatide replicates this glucose-dependent amplification at both receptor systems simultaneously.
Receptor binding studies demonstrate that tirzepatide exhibits roughly equal potency at the GIPR and GLP-1R, though its maximal efficacy (Emax) at GLP-1R is somewhat lower than that of a full GLP-1R agonist such as semaglutide. Researchers initially hypothesized this partial agonism at GLP-1R might limit efficacy, but clinical results suggest the combined receptor engagement more than compensates. The GIP receptor component appears to provide additive or synergistic insulin secretagogue effects and may also mitigate some of the gastrointestinal side effects associated with pure GLP-1R agonism by modulating gastric motility pathways somewhat differently.
The GIP receptor is expressed not only in pancreatic islets but also abundantly in adipose tissue — both subcutaneous and visceral depots. Activation of adipocyte GIPRs promotes lipoprotein lipase activity and facilitates fatty acid uptake during the postprandial period under normal physiological conditions, but in obese, insulin-resistant states, this pathway becomes dysregulated. Tirzepatide’s engagement of adipose GIPR appears to partially restore normal lipid partitioning, reducing the preferential accumulation of ectopic fat in the liver and skeletal muscle.
Preclinical studies using GIPR knockout models and selective GIPR antagonists helped establish that GIP receptor signaling in adipose tissue is necessary for tirzepatide to achieve its full weight-loss effect, distinct from the anorectic contribution of GLP-1R activation. Additionally, GIP receptors in the hypothalamus may modulate energy expenditure directly, though the relative contribution of central versus peripheral GIPR signaling to tirzepatide’s metabolic effects remains an active research question. Brown adipose tissue thermogenesis appears upregulated in rodent models treated with dual GIPR/GLP-1R agonists, a mechanism researchers are now attempting to quantify in humans using PET-CT imaging of brown fat activation.
The GLP-1 receptor component of tirzepatide’s mechanism mediates appetite suppression through well-characterized central and peripheral pathways. In the hypothalamus, GLP-1R activation reduces the firing rate of orexigenic (appetite-promoting) neuropeptide Y and AgRP neurons while increasing the activity of anorexigenic POMC neurons, shifting the homeostatic set point toward reduced caloric intake. GLP-1R agonism in the nucleus tractus solitarius of the brainstem reinforces satiety signaling relayed from vagal afferents innervating the stomach and duodenum.
Peripherally, GLP-1R activation slows gastric emptying, which extends the duration of postprandial satiety and reduces postprandial glucose excursions by slowing the rate at which nutrients enter the small intestine. Tirzepatide’s effect on gastric emptying is dose-dependent and appears somewhat attenuated compared to high-dose semaglutide, potentially contributing to its relatively favorable gastrointestinal tolerability profile. GLP-1R signaling in the liver independently reduces hepatic glucose production by inhibiting glycogenolysis and gluconeogenesis, contributing to fasting glucose control that complements the insulin-secretagogue effects at the pancreatic level.
The SURPASS clinical program comprised six Phase 3 trials enrolling over 6,000 participants with type 2 diabetes across diverse backgrounds and treatment histories. SURPASS-1, conducted in drug-naive patients, demonstrated dose-dependent HbA1c reductions of 1.87% (5 mg), 1.89% (10 mg), and 2.07% (15 mg) from a mean baseline of approximately 7.9%, with 31–52% of participants achieving normoglycemia (HbA1c below 5.7%). Body weight fell by 7–9.5 kg across dose groups over 40 weeks.
SURPASS-2 compared tirzepatide head-to-head with semaglutide 1 mg in over 1,800 participants inadequately controlled on metformin. Tirzepatide at all three doses produced superior HbA1c reductions (differences of 0.45–0.74 percentage points) and significantly greater weight loss (differences of 1.9–5.5 kg). This trial was among the first direct comparisons to show a next-generation dual agonist substantially outperforming the leading GLP-1R agonist of its era. SURPASS-4 and SURPASS-5 addressed patients with higher cardiovascular risk profiles and those on insulin therapy, respectively, with tirzepatide demonstrating consistent glycemic and weight benefits while allowing insulin dose reductions in the majority of participants.
Long-term extension data from SURPASS-CVOT followed over 13,000 participants with type 2 diabetes and established cardiovascular disease for a median of approximately 4.5 years, providing the definitive cardiovascular safety and efficacy readout for this population.
The SURMOUNT program redefined expectations for pharmacological weight management. SURMOUNT-1 enrolled 2,539 adults without diabetes who had a BMI of 30 or greater (or 27+ with at least one weight-related comorbidity). Participants randomized to tirzepatide 5 mg, 10 mg, or 15 mg achieved mean weight reductions of 15.0%, 19.5%, and 20.9% respectively at 72 weeks, compared with 3.1% in the placebo group. The proportion achieving at least 20% body weight loss was 57% in the 15 mg group — a result that had been considered the exclusive domain of bariatric surgery.
SURMOUNT-2 replicated these findings in participants with type 2 diabetes, where mean weight loss of 14.7% (15 mg) was still substantially greater than results from any prior diabetes pharmacotherapy. SURMOUNT-3 and SURMOUNT-4 were particularly noteworthy for their assessment of treatment durability. SURMOUNT-4 used a withdrawal design: participants who had lost weight on tirzepatide during a lead-in phase were randomized to either continue tirzepatide or switch to placebo. Those who switched regained nearly 14% of their body weight over the following year, underscoring the sustained biological mechanisms underlying obesity and the ongoing medication requirements for weight maintenance.
Metabolic dysfunction-associated steatotic liver disease (MASLD) affects a large proportion of people with obesity and type 2 diabetes. Dedicated imaging substudies within the SURPASS and SURMOUNT programs, as well as independent mechanistic trials, have used MRI-based proton density fat fraction (PDFF) measurements and liver biopsy to characterize tirzepatide’s hepatic effects in detail.
A Phase 2 trial (NCT04166773) specifically in participants with MASH and fibrosis (F1–F3) randomized participants to tirzepatide 5, 10, or 15 mg versus placebo for 52 weeks. Liver biopsy at end-of-treatment showed MASH resolution without worsening of fibrosis in 44% (5 mg), 56% (10 mg), and 62% (15 mg) of participants, compared with 10% in the placebo group. Fibrosis improvement of at least one stage occurred in 55% of participants on the 15 mg dose. These histological results supported the initiation of SYNERGY-NASH, a Phase 3 confirmatory trial. Reductions in alanine aminotransferase, aspartate aminotransferase, and hepatic fat fraction on MRI tracked consistently with biopsy improvements, providing non-invasive surrogate markers for ongoing monitoring.
Cardiovascular disease and obesity are deeply intertwined, and establishing that a weight-loss therapy actually reduces cardiovascular events — rather than merely improving surrogate markers — is a high evidentiary bar. The SURMOUNT-MMO trial (also identified as CVOT for the obesity indication) was a dedicated event-driven trial enrolling over 15,000 adults aged 45 years and older with established cardiovascular disease and a BMI of 27 or higher but without diabetes.
The primary endpoint — a composite of cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke — was reduced by 17% in the tirzepatide group relative to placebo (hazard ratio 0.83, 95% CI 0.72–0.95, p=0.0066). These results, presented at the American Diabetes Association Scientific Sessions in June 2024, made tirzepatide only the second pharmacological weight-loss agent after semaglutide to demonstrate a statistically significant MACE reduction in a prospective outcomes trial. Investigators noted that the cardiovascular benefit appeared to extend beyond what would be predicted from weight loss alone, suggesting direct cardiometabolic effects of GIP and GLP-1 receptor signaling on myocardial, vascular, and inflammatory pathways.
Diabetic kidney disease is the leading cause of end-stage renal failure in many countries, and early data suggest tirzepatide may have protective effects in this context. Secondary renal endpoints from SURPASS-4, which specifically enrolled patients with type 2 diabetes and high cardiovascular risk (many of whom had baseline CKD), showed tirzepatide significantly reduced urine albumin-to-creatinine ratio compared with insulin glargine, a marker of glomerular filtration barrier integrity.
The SURPASS-CVOT renal substudy tracked eGFR trajectories over the trial duration and found a 32% reduction in a composite kidney outcome (sustained 40% decline in eGFR, kidney failure, or death from renal causes) in the tirzepatide group. A dedicated kidney outcomes trial, TREASURE, was initiated to provide a prospective primary endpoint evaluation of tirzepatide’s nephroprotective effects in participants with CKD and albuminuria. Mechanistically, renal benefits are thought to derive from reduced intraglomerular hypertension (mediated via natriuresis and blood pressure reduction), direct GLP-1 receptor effects on tubular epithelial cells, and reduced progression of glomerulosclerosis linked to adiposity-driven inflammation.
Tirzepatide has been studied across three maintenance doses: 5 mg, 10 mg, and 15 mg administered once weekly. All approved clinical protocols begin with an escalation schedule to minimize gastrointestinal side effects during treatment initiation. The standard escalation used across SURPASS and SURMOUNT trials begins at 2.5 mg per week for the first four weeks, then increases by 2.5 mg increments every four weeks until the target maintenance dose is reached.
Reaching 15 mg therefore requires approximately 20 weeks of dose escalation from initiation. Some participants in trials were maintained at lower doses (5 mg or 10 mg) if they experienced tolerability issues at higher doses or achieved satisfactory glycemic and weight outcomes at a lower maintenance level. Preclinical dose-finding studies in rodents and non-human primates used weight-based dosing (typically 0.1–10 nmol/kg), but direct translation to human dosing is not linear due to differences in receptor distribution and pharmacokinetics across species.
All clinical and approved uses of tirzepatide involve subcutaneous injection. The compound is supplied as a pre-filled autoinjector pen or vial formulation in aqueous solution at concentrations appropriate for the target dose volume. Injection sites in trials included the abdomen, thigh, and upper arm, with rotation between sites recommended to minimize local reactions.
Intravenous and intramuscular routes have not been studied in clinical trials and are not part of any approved protocol. The subcutaneous route provides a predictable absorption profile with time to peak plasma concentration (Tmax) of approximately 8–72 hours after injection, consistent with the slow release from the subcutaneous depot facilitated by the fatty acid-albumin binding mechanism. Oral formulations have been explored in early-stage Eli Lilly research programs, mirroring oral semaglutide development, but no oral tirzepatide candidate has entered advanced clinical trials as of early 2026.
Once-weekly administration is the sole frequency used in all clinical studies. The five-day half-life of tirzepatide supports weekly dosing with minimal peak-to-trough fluctuation in plasma concentrations, in contrast to shorter-acting GLP-1R agonists such as exenatide twice-daily or liraglutide once-daily. Steady-state plasma concentrations are reached after approximately two to three weeks of weekly dosing.
Injection timing relative to meals does not significantly affect tirzepatide’s pharmacokinetics, unlike some oral antidiabetic agents that require fasting administration. Participants in trials administered injections on a consistent day each week, but a missed dose could be administered up to four days late without restarting the weekly schedule. Beyond four days, participants were instructed to skip the missed dose and resume on the next scheduled day.
Commercial tirzepatide (Mounjaro and Zepbound) is supplied as a ready-to-inject solution and does not require reconstitution. For research settings using bulk lyophilized tirzepatide, standard reconstitution involves dissolving the lyophilized peptide in sterile bacteriostatic water or an appropriate buffer (typically phosphate-buffered saline at pH 7.4) at a concentration that delivers the target dose in an injection volume of 0.5–1.0 mL.
Reconstituted peptide solutions should be stored at 2–8°C (refrigerator temperature) and are generally considered stable for 28 days under these conditions when kept protected from light. Freezing of reconstituted solutions is not recommended as it may promote aggregation. Lyophilized powder, prior to reconstitution, can typically be stored at -20°C for longer-term archival purposes. Researchers working with tirzepatide in preclinical models should refer to the specific certificate of analysis from their peptide supplier for validated stability data under experimental conditions. Use our peptide dosing calculator to assist with dilution and dose preparation.
Rodent carcinogenicity studies conducted as part of the regulatory package identified dose-dependent thyroid C-cell hyperplasia and, at very high doses, C-cell adenomas and carcinomas in rats and mice. This finding, shared by all GLP-1R agonist class members, is attributed to the high density of GLP-1 receptors on rodent thyroid C cells — a distribution not replicated in human or non-human primate thyroid tissue at comparable levels. Calcitonin levels, the clinical surrogate for C-cell activity, have not shown meaningful elevations in human clinical trials, and no cases of medullary thyroid carcinoma attributable to tirzepatide have been reported across the entire SURPASS and SURMOUNT programs.
Reproductive toxicology studies in rats showed fetal growth retardation and skeletal anomalies at doses that also produced significant maternal weight loss and food intake reduction, effects interpreted as secondary to caloric restriction rather than direct fetal teratogenicity. However, because the clinical relevance of these findings cannot be fully excluded, tirzepatide carries a contraindication in pregnancy across all regulatory jurisdictions.
In human trials, the most frequently reported adverse events are gastrointestinal in nature: nausea, vomiting, diarrhea, and constipation. These effects are dose-dependent, most prominent during dose escalation, and typically transient. In SURMOUNT-1, nausea was reported by approximately 31% of participants in the 15 mg group versus 6% in the placebo group, but fewer than 5% discontinued treatment due to gastrointestinal side effects, reflecting the mitigation afforded by gradual dose escalation.
Hypoglycemia risk is low when tirzepatide is used as monotherapy or with metformin, because insulin secretion is glucose-dependent. The risk increases meaningfully when tirzepatide is combined with sulfonylureas or insulin, as seen in SURPASS-3 and SURPASS-4, where insulin dose reductions were often required upon tirzepatide initiation. Injection site reactions (erythema, bruising, nodules) were reported in 3–7% of participants and were generally mild and self-limiting. Rare cases of acute pancreatitis have been reported, consistent with GLP-1R agonist class labeling, though causality in individual cases is difficult to establish given that diabetes and obesity independently increase pancreatitis risk.
While tirzepatide’s clinical evidence base is extensive, several important research gaps remain. The long-term safety profile beyond five years has not been established in prospective controlled data. The question of optimal duration of therapy — and whether finite-duration treatment courses might produce durable metabolic benefits — remains unanswered; SURMOUNT-4’s withdrawal data suggest ongoing treatment is necessary to maintain weight loss for most individuals, but longer-term trials with structured treatment holidays are needed.
The relative contributions of GIP receptor versus GLP-1 receptor engagement to tirzepatide’s metabolic effects are still being dissected in ongoing mechanistic studies. Receptor selectivity profiling in different tissue compartments (pancreas, adipose, brain, liver, kidney) using positron emission tomography tracers and receptor-specific antagonists is an active area of investigation. Additionally, inter-individual variability in treatment response is substantial — some participants lose less than 5% body weight while others exceed 30% — and the genetic, metabolic, and microbiome factors that predict response remain poorly characterized. Researchers can explore ongoing mechanistic questions using the peptide database to cross-reference receptor binding profiles.
Semaglutide is a selective GLP-1 receptor agonist, meaning it activates only one incretin receptor. Tirzepatide activates both the GLP-1 receptor and the GIP receptor simultaneously, engaging two distinct but complementary metabolic pathways. In direct head-to-head clinical trials (SURPASS-2 and the SURMOUNT-based comparisons), tirzepatide consistently produced greater HbA1c reductions and greater body weight loss than semaglutide at clinically approved doses. The mechanisms underlying this superior efficacy are still being fully characterized, but the additive GIP receptor engagement — particularly its effects on adipose tissue fat metabolism and potentially on energy expenditure — is believed to be a major contributor. Both compounds are once-weekly subcutaneous injections with similar gastrointestinal side effect profiles during initiation.
Yes. Mounjaro and Zepbound are both brand names for the same active ingredient, tirzepatide. The difference lies solely in the FDA-approved indication. Mounjaro was approved in May 2022 for glycemic control in adults with type 2 diabetes and is labeled and marketed in that context. Zepbound received approval in November 2023 specifically for chronic weight management in adults with obesity or overweight with a qualifying comorbidity. The drug product itself — the same 39-amino acid peptide at the same doses — is chemically identical. Some prescribers write for one brand when the primary goal is diabetes management and the other when the primary goal is weight reduction, largely based on insurance coverage differences between the two indications.
The SURMOUNT-1 trial, which enrolled adults with obesity but without diabetes, reported the most dramatic results. At the 15 mg dose over 72 weeks, mean body weight loss was 20.9%. More strikingly, approximately 57% of participants in that dose group achieved at least 20% total body weight loss, and a substantial proportion exceeded 25%. These magnitudes had previously been associated only with bariatric surgical procedures such as Roux-en-Y gastric bypass. Individual participants in the trial achieved weight reductions exceeding 35%. The SURMOUNT-2 trial, which enrolled participants with type 2 diabetes, also achieved 14.7% mean weight loss at 15 mg — lower than in the non-diabetic population but still the largest pharmacological weight reduction ever documented in a large randomized controlled trial for patients with diabetes at the time of publication.
Yes, and this is one of the most clinically significant findings to emerge from the tirzepatide research program. A dedicated Phase 2 trial in participants with biopsy-confirmed MASH (the active inflammatory form of metabolic liver disease) demonstrated MASH resolution without worsening fibrosis in 44–62% of participants across the three dose groups, compared with 10% on placebo. Fibrosis improvement of at least one stage occurred in roughly half of participants on the highest dose. These results represent some of the strongest histological data for any pharmacotherapy in MASH to date and supported initiation of the Phase 3 SYNERGY-NASH confirmatory trial. MRI-measured liver fat fraction also declined significantly in multiple SURPASS and SURMOUNT imaging substudies, providing a non-invasive corroboration of the biopsy findings.
This question arises from rodent carcinogenicity studies that identified thyroid C-cell tumors at high doses in rats and mice — a finding shared across the entire GLP-1R agonist drug class. However, rodent thyroid C cells express GLP-1 receptors at much higher density than human C cells, meaning direct extrapolation from rodent tumor data to human risk is not supported by current evidence. Across tens of thousands of patient-years of exposure in clinical trials and post-marketing surveillance, no signal for medullary thyroid carcinoma (the C-cell tumor type) has emerged. Calcitonin levels, the clinical biomarker for C-cell stimulation, have not meaningfully elevated in trial participants. Regulatory agencies in the US and EU nonetheless maintain a precautionary contraindication for individuals with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 (MEN2).
Glycemic improvements are often detectable within the first two to four weeks of treatment as incretin-mediated insulin secretion and gastric emptying slowing take effect, even at the starting 2.5 mg dose. Meaningful weight loss typically begins to accelerate after the dose escalation period, with the most rapid rate of weight reduction occurring between weeks 12 and 36 in most participants. Plateau typically occurs somewhere between weeks 60 and 88 depending on the individual. The SURMOUNT-1 weight loss curves suggest that participants have generally not fully plateaued by 72 weeks at the highest dose, implying that longer treatment durations may yield additional weight loss. Liver enzyme improvements and reductions in blood pressure and triglycerides are typically apparent within the first 12–16 weeks.
SURMOUNT-4 provides the most rigorous answer. In that trial, participants who lost a mean of 20.9% of body weight during a 36-week open-label tirzepatide lead-in were randomized to continue tirzepatide or switch to placebo for a further 52 weeks. Those who switched to placebo regained a mean of 13.9% of body weight — essentially reversing most of the weight lost — while those who continued tirzepatide maintained and modestly extended their losses. These data confirm that obesity functions as a chronic disease requiring ongoing treatment, similar to hypertension or diabetes. Glycemic markers also worsened upon discontinuation in participants with type 2 diabetes. This pattern mirrors findings from semaglutide withdrawal studies, suggesting it reflects a general property of incretin-mediated weight loss pharmacotherapy rather than a tirzepatide-specific phenomenon.
Yes. The SUMMIT trial investigated tirzepatide in patients with heart failure with preserved ejection fraction (HFpEF) and obesity, a population for which effective pharmacological options have historically been limited. Results published in late 2024 showed tirzepatide significantly improved the primary endpoint of a composite of cardiovascular death or worsening heart failure events, along with meaningful improvements in exercise capacity, symptom burden (Kansas City Cardiomyopathy Questionnaire scores), and body weight. The FDA subsequently added HFpEF with obesity as a Zepbound indication in 2025. These findings are consistent with earlier data showing semaglutide improved HFpEF outcomes and suggest that incretin receptor-mediated weight loss confers specific benefits in this syndrome that go beyond simply reducing body mass. The AI coach can help you navigate the growing evidence base for tirzepatide in cardiovascular applications.
Disclaimer: This information is for research and educational purposes only. It is not medical advice. Consult a qualified healthcare professional before using any peptide.